Regine Kluge

Regine Kluge

Auto-generated profile, based on publicly available information

Regine Kluge

Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2014 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
DHDirk Hasenclever
Dirk Hasenclever
LKLars Kurch
Lars Kurch
CMChristine Mauz-Körholz
Christine Mauz-Körholz
AEAndreas Elsner
Andreas Elsner
TGThomas Georgi
Thomas Georgi
RKRegine Kluge
Regine Kluge

1 May 2017 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
RKRegine Kluge
Regine Kluge
LKL. Kurch
L. Kurch
TGThomas Georgi
Thomas Georgi
MMMonika Metzger
Monika Metzger

24 March 2013 in Pediatric Radiology
Verified
Journal Article
Closed access
PDF file
RKRegine Kluge
Regine Kluge
LKLars Kurch
Lars Kurch
FMFrançoise Montravers
Françoise Montravers
CMChristine Mauz-Körholz
Christine Mauz-Körholz

10 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RKRegine Kluge
Regine Kluge
LCLidia Chavdarova
Lidia Chavdarova
MHMartha Hoffmann
Martha Hoffmann
CKCarsten Kobe
Carsten Kobe
BMBogdan Małkowski
Bogdan Małkowski
DHDirk Hasenclever
Dirk Hasenclever
The five point Deauville (D) scale is widely used to assess interim PET metabolic response to chemotherapy in Hodgkin lymphoma (HL) patients. An International Validation Study reported good concordance among reviewers in ABVD treated advanced stage HL patients for the binary discrimination between score D1,2,3 and score D4,5. Inter-reader reliability of the whole scale is not well characterised. Five international expert readers scored 100 interim PET/CT scans from paediatric HL patients. Scans were acquired in 51 European hospitals after two courses of OEPA chemotherapy (according to the EuroNet-PHL-C1 study). Images were interpreted in direct comparison with staging PET/CTs. The probability that two random readers concord on the five point D score of a random case is only 42% (global kappa = 0.24). Aggregating to a three point scale D1,2 vs. D3 vs. D4,5 improves concordance to 60% (kappa = 0.34). Concordance if one of two readers assigns a given score is 70% for score D1,2 only 36% for score D3 and 64% for D4,5. Concordance for the binary decisions D1,2 vs. D3,4,5 is 67% and 86% for D1,2,3 vs D4,5 (kappa = 0.36 resp. 0.56). If one reader assigns D1,2,3 concordance probability is 92%, but only 64% if D4,5 is called. Discrepancies occur mainly in mediastinum, neck and skeleton. Inter-reader reliability of the five point D-scale is poor in this interobserver analysis of paediatric patients who underwent OEPA. Inter-reader variability is maximal in cases assigned to D2 or D3. The binary distinction D1,2,3 versus D4,5 is the most reliable criterion for clinical decision making.

27 April 2006 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MFMathias Fasshauer
Mathias Fasshauer
TLThomas Lincke
Thomas Lincke
HWHelmut Witzigmann
Helmut Witzigmann
RKRegine Kluge
Regine Kluge
ATAndrea Tannapfel
Andrea Tannapfel
CKChristian A Koch
Christian A Koch
ACTH overproduction within the pituitary gland or ectopically leads to hypercortisolism. Here, we report the first case of Cushing' syndrome caused by an ectopic ACTH-secreting neuroendocrine carcinoma of the mesentery. Moreover, diagnostic procedures and pitfalls associated with ectopic ACTH-secreting tumors are demonstrated and discussed. A 41 year-old man presented with clinical features and biochemical tests suggestive of ectopic Cushing's syndrome. First, subtotal thyroidectomy was performed without remission of hypercortisolism, because an octreotide scan showed increased activity in the left thyroid gland and an ultrasound revealed nodules in both thyroid lobes one of which was autonomous. In addition, the patient had a 3 mm hypoenhancing lesion of the neurohypophysis and a 1 cm large adrenal tumor. Surgical removal of the pituitary lesion within the posterior lobe did not improve hypercortisolism and we continued to treat the patient with metyrapone to block cortisol production. At 18-months follow-up from initial presentation, we detected an ACTH-producing neuroendocrine carcinoma of the mesentery by using a combination of octreotide scan, computed tomography scan, and positron emission tomography. Intraoperatively, use of a gamma probe after administration of radiolabeled 111In-pentetreotide helped identify the mesenteric neuroendocrine tumor. After removal of this carcinoma, the patient improved clinically. Laboratory testing confirmed remission of hypercortisolism. An octreotide scan 7 months after surgery showed normal results. This case underscores the diagnostic challenge in identifying an ectopic ACTH-producing tumor and the pluripotency of cells, in this case of mesenteric cells that can start producing and secreting ACTH. It thereby helps elucidate the pathogenesis of neuroendocrine tumors. This case also suggests that patients with ectopic Cushing's syndrome and an octreotide scan positive in atypical locations may benefit from explorative radioguided surgery using 111In-pentetreotide and a gamma probe.

20 January 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
TGThomas Walter Georgi
Thomas Walter Georgi
LKLars Kurch
Lars Kurch
GFGeorg-Nikolaus Franke
Georg-Nikolaus Franke
MJMadlen Jentzsch
Madlen Jentzsch
SSSebastian Schwind
Sebastian Schwind
VVVladan Vucinic
Vladan Vucinic
Purpose: Chimeric antigen receptor (CAR)-T cells are a viable treatment option for patients with relapsed or refractory (r/r) aggressive B-cell lymphomas. The prognosis of patients who relapse after CAR-T cell treatment is dismal and factors predicting outcomes need to be identified. Our aim was to assess the value of FDG-PET/CT in terms of predicting patient outcomes. Methods: Twenty-two patients with r/r B-cell lymphoma who received CAR-T cell treatment with tisagenlecleucel (n = 17) or axicabtagene ciloleucel (n = 5) underwent quantitative FDG-PET/CT before (PET-0) and 1 month after infusion of CAR-T cells (PET-1). PET-1 was classified as complete metabolic response (CMR, Deauville score 1–3) or non-CMR (Deauville score 4–5). Results: At the time of PET-1, 12/22 (55%) patients showed CMR, ten (45%) patients non-CMR. 7/12 (58%) CMR patients relapsed after a median of 223 days, three of them (25%) died. 9/10 (90%) non-CMR patients developed relapse or progressive disease after a median of 91 days, eight of them (80%) died. CMR patients demonstrated a significantly lower median total metabolic tumor volume (TMTV) in PET-0 (1 ml) than non-CMR patients (225 ml). Conclusion: Our results confirm the prognostic value of PET-1. 42% of all CMR patients are still in remission 1 year after CAR T-cell treatment. 90% of the non-CMR patients relapsed, indicating the need for early intervention. Higher TMTV before CAR-T cell infusion was associated with lower chances of CMR.